Obalon Therapeutics Inc. Announces Pricing of $15,000,000 Public Offering
The gross offering proceeds to the Company from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, and excluding the exercise of any warrants and the underwriters’ option to purchase additional shares, are expected to be approximately
The Company intends to use the net proceeds from this offering to launch its transition to company-owned or managed Obalon-branded retail centers, and for general corporate purposes.
A registration statement on Form S-1 (No. 333-232276) relating to the offering was filed with the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
To the extent that statements contained in this press release are not descriptions of historical facts regarding
President & Chief Financial Officer
Office: +1 760 607 5103
Source: Obalon Therapeutics, Inc.